2023 China Reproductive Health Industry Research Report - Simplified Version Source: iResearch Consulting
China Reproductive Health Industry Report 2023
Assisted Reproduction · Prenatal Screening · Industry trends
Reproductive health industry covers a continuum of medical services: screening, pre-conception, prenatal, delivery, and postnatal care. It targets improved birth outcomes and aligns with national strategies. Assisted reproductive technology (ART) and prenatal screening/diagnostics are key focuses of this report.
China’s population structure shifted from pyramid (2000) to olive shape (2022).
By 2050, an inverted pyramid could emerge, causing labor shortages and stress on healthcare resources.
Urgent fertility policy adjustments are necessary.
Three-child policy enacted.
In 2022, 17 central departments mandated including assisted reproduction into medical insurance coverage.
Beijing led the way by adding 16 ART items to its insurance scheme.
Pro-natalist and reproductive health promotion plans are expanding nationwide.
Per capita disposable income reached ¥37,000 in 2022.
Per capita healthcare expenditure: ¥2,120, accounting for 8.6% of total consumption (up 1.6pp vs 2012).
Stronger willingness to pay fortifies the reproductive health market.
Reproductive health fulfills needs for safety, love/belonging, and self-actualization.
Universal access to reproductive care reflects social progress and is vital to people’s livelihood.
🔬 Upstream: domestic substitution accelerates
Reagents and consumables have achieved high localization rates (three stars).
Pharmaceuticals and high-end devices still rely partly on imports (e.g., cryopreservation media, ovulation inductors).
Policy push & R&D advances drive replacement of gonadotropins, incubators, and testing kits.
| Sector | Localization level | Examples of localized products |
|---|---|---|
| Diagnostic reagents | ★★★ | hCG/Pregnancy test kits, progesterone assays |
| Drugs | ★★★ | Clomiphene, gonadotropins |
| Medical devices | ★★ | Ultrasound systems (partial), embryo incubators (import dependency remains) |
🏥 Midstream: labs & customized care
LDT (lab-developed test) pilots enhance precision.
Embryologists and physicians are integral to ART success.
Institutions emphasize personalized treatment plans and patient-centric service systems.
Quality and experience become competitive differentiators.
Online platforms like “Sowing Net” integrate information management systems.
Through big data, they analyze user needs, optimize content, and guide patients to appropriate offline providers.
This boosts resource efficiency and builds a reproductive health ecosystem.
🤱 Assisted Reproduction (ART)
Infertility rate expected to reach 18.2% in 2023 (The Lancet).
ART market to reach RMB 48.4 billion by 2026.
Penetration rate in China: 8.2% (2021) vs 32% in the U.S. – huge growth runway.
As of 2020: 536 licensed ART institutions (91% public).
Stringent quota: 1 center per 2.3–3 million population.
Private players expand via talent acquisition and service quality.
China’s ART success rates (40-60%) on par with global standards.
Japan allows single women egg freezing; U.S. surrogacy-friendly states.
Chinese law restricts ART to infertile married couples, surrogacy banned.
IUI → IVF (ovarian stimulation → egg retrieval → fertilization → embryo culture → PGT)
One IVF cycle takes 2–3 months; many patients undergo 2-3 cycles.
🧬 Prenatal Screening & Diagnosis: NIPT as a game-changer
Prenatal diagnosis rate reached 97.6% in 2021.
Infant mortality dropped to 5‰ (2021).
NIPT detection rate >99.99% with zero miscarriage risk.
NIPT surpasses traditional serum screening (60-80% sensitivity) and ultrasound (70%).
2026e NIPT market: RMB 13.3 billion.
- Non-invasive: maternal peripheral blood only
- High accuracy for trisomy 21/18/13
- Turnaround: 1-2 weeks
- Detection of sex chromosome aneuploidies & microdeletions
| Method | Miscarriage risk | Detection rate | Turnaround |
|---|---|---|---|
| NIPT | 0 | >99.99% | 1-2 weeks |
| Amniocentesis | 0.5-1% | >99% | 3-4 weeks |
| Ultrasound | 0 | ~70% | Immediate |
Leading private ART provider in China.
High IVF cycle volume and success rates.
Global footprint across China, Laos, and the U.S.
Strategy: scale expansion + service integration for full life-cycle reproductive health.
Industry benchmark Global platformPioneer in NIPT and genetic testing.
“Product + Service” solutions for medical institutions.
High market share in non-invasive prenatal testing, with continuous R&D on advanced sequencing platforms.
NIPT leaderDigital fertility platform with >1 million monthly active users.
AI-driven fertility consultation, big-data analysis, and at-home testing + AI diagnostics.
Building a vertical reproductive telemedicine ecosystem.
digital health enablerAI, gene editing, and precision medicine reshape the industry chain.
Online platforms build closed-loop reproductive health services, enabling personalized care.
Lab-developed tests accelerate the launch of innovative diagnostics.
They alleviate resource shortages and benefit device, reagent, and service providers.
NIPT sets the standard for non-invasive prenatal testing.
Assisted reproductive drugs: oral formulations gradually replacing suppositories/injections, improving patient compliance and accelerating domestic substitution.
Genetic factors cause 15-30% of male infertility and 5-10% of female infertility.
Precise genetic diagnosis guides patients to effective ART, reducing treatment costs and improving success rates.
China’s reproductive health industry is on a high-growth trajectory driven by policy, technology, and demand. Assisted reproduction penetration is set to expand; NIPT technology leads prenatal care; domestic substitution and precision medicine gather momentum. The future points to accessible, intelligent, and patient-centered reproductive health for all.
Special thanks to Jinxin Reproductive Medicine, Berry Genomics, and Sowing Network for their industry insights and support.
Data sources: National Bureau of Statistics, National Health Commission, The Lancet, iResearch proprietary research and analysis.
This page presents key insights from iResearch “China Reproductive Health Industry Report 2023” for educational purposes only. Commercial use prohibited.
© iResearch Inc. | Layout optimized with free commercial fonts Inter & Noto Serif
